Evaluating a new hydrogel system for prostate cancer treatment

SpaceIT Hydrogel System for Perirectal Spacing in Subjects With Low to Intermediate Risk Prostate Cancer Undergoing External Beam Radiotherapy (EBRT)

This study is testing a new hydrogel system to see if it can improve treatment for prostate cancer patients receiving radiation therapy compared to a standard hydrogel.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 230 (estimated)
• Ages: 18 Years and up
• Sex: Male
• Sponsor: Boston Scientific Corporation (Industry-sponsored)
• Locations: 13 sites (Miami, Florida and 12 other locations)
• Trial ID: NCT06451614 on ClinicalTrials.gov

What this trial studies

This study evaluates the safety and effectiveness of the SpaceIT Hydrogel System in patients undergoing External Beam Radiotherapy (EBRT) for prostate cancer. It is a prospective, randomized, multicenter trial where participants will be assigned to either the investigational SpaceIT Hydrogel or a commercially available hydrogel spacer. The aim is to determine if the new hydrogel can improve treatment outcomes compared to existing options.

Who should consider this trial

Good fit: Ideal candidates are adult males aged 18 and older with confirmed invasive adenocarcinoma of the prostate planning to undergo EBRT.

Not a fit: Patients with prostate volumes greater than 80 cc or those planning to undergo brachytherapy or focal boost may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a more effective hydrogel spacer that enhances the safety and efficacy of radiotherapy for prostate cancer patients.

How similar studies have performed: Other studies have shown success with similar hydrogel spacer approaches, indicating potential for this new system.

Eligibility criteria

Inclusion Criteria:

Subjects must meet the following criteria to be eligible for participation in the study:

1. Age ≥18 years old
2. Subjects must have had pathologically confirmed (by routine hematoxylin and eosin \[H\&E\] staining) invasive adenocarcinoma of the prostate and planning to undergo EBRT
3. Subjects must meet ALL of the following:

   1. Clinical stage T1-T2c (AJCC Ver. 8) tumor AND
   2. Gleason Score 7 or less as determined from a biopsy taken within 12 months of the Baseline visit AND
   3. Demonstrated blood prostate specific antigen (PSA) levels ≤20 ng/ml as measured within 6 months of the Baseline visit and prior to commencing androgen deprivation therapy (ADT)
4. Subject is able to provide written informed consent, approved by the appropriate Institutional Review Board/Ethics Committee/Research Ethics Board (IRB/EC/REB) of the respective clinical site

Exclusion Criteria:

1. Prostate \> 80 cc
2. Subjects who are planning to undergo brachytherapy or focal boost
3. Subjects who have magnetic resonance imaging (MRI) evidence of gross posterior extracapsular extension (ECE) of the prostate cancer Note: MRI must be taken within 6 months prior to the Baseline visit
4. Subjects who have metastatic disease, other ongoing cancers which are being treated during the study or subjects for whom pelvic lymph node radiotherapy is planned
5. Subjects with any prior invasive solid tumor malignancy or hematologic malignancy (except non-melanomatous skin cancer) unless the subject has been disease free and treatment free for a minimum of 3 years
6. History of radical prostatectomy, other ablative anti-prostate cancer therapy (e.g., cryotherapy, high intensity focused ultrasound, irreversible electroporation) or previous pelvic irradiation (including prior prostate brachytherapy) at any time prior to screening
7. History of transurethral prostate surgery (e.g., Transurethral Needle Ablation (TUNA), Transurethral Microwave Therapy (TUMT), Transurethral Resection of the Prostate (TURP)) if performed within 1 year prior to screening
8. History of prior pelvic surgery requiring low anterior or abdominoperineal resections or rectal surgery
9. History of or current perirectal disease that may interfere with interpretation of study outcomes, including anal or perianal diseases such as fistula
10. Bleeding hemorrhoids requiring medical intervention within the prior three months
11. Diagnosed active bleeding disorder or a clinically significant coagulopathy, defined as PTT \> 70s or aPTT\>35s or INR \> 1.4, or platelet count \< 100,000 per mm3 Note: Subjects on anticoagulants may be included if the anticoagulant medication can be held for index procedure
12. Active inflammatory or infectious process involving the perineum, GI or urinary tract based on positive diagnosis or suspected diagnosis in the presence of fever \>38⁰ C, WBC \> 12,000/uL
13. Inability to undergo pelvic MRI or presence of implants causing severe artifact (e.g. bilateral arthroplasty) that interferes with imaging interpretation for this study at Investigator discretion
14. If a subject was enrolled in another investigational drug or device trial that had not completed the primary endpoint or that clinically interfered with this study
15. Unable to comply with the study requirements or follow-up schedule
16. Any condition the Investigator believed would interfere with the intent of the study or would make participation not in the best interest of the patient
17. Known PEG (polyethylene glycol) sensitivity or allergy
18. Known iodine sensitivity or allergy
19. ADT, if applicable, cannot or was not started 15-60 days prior to the pre-index procedure RT planning imaging and is planned to continue for a total planned duration greater than 6 months

Where this trial is running

Miami, Florida and 12 other locations

• Baptist Hospital of Miami — Miami, Florida, United States (Recruiting)
• Orlando Health Cancer Institute — Orlando, Florida, United States (Recruiting)
• Emory University Hospital — Atlanta, Georgia, United States (Recruiting)
• Associated Urological Specialists — Chicago Ridge, Illinois, United States (Recruiting)
• UroPartners — Glenview, Illinois, United States (Recruiting)
• Springfield Clinic, LLC — Springfield, Illinois, United States (Recruiting)
• University of Kansas Hospital — Kansas City, Kansas, United States (Recruiting)
• Integrated Medical Professionals — New York, New York, United States (Recruiting)
• Perlmutter Cancer Center - NYU Langone — New York, New York, United States (Recruiting)
• MidLantic Urology — Bala Cynwyd, Pennsylvania, United States (Recruiting)
• Gibbs Cancer Center and Research Institute — Greer, South Carolina, United States (Recruiting)
• Houston Metro Urology — Houston, Texas, United States (Recruiting)
• Evergreen Hospital Medical Center — Kirkland, Washington, United States (Recruiting)

Study contacts

• Principal investigator: Brian Baumann, MD — Springfield Clinic
• Study coordinator: Kaitlyn Rainbow

Conditions Prostate Cancer